Navigation Links
Cardium Reports on Presentation at American Heart Association Meeting Relating to Gene Delivery to the Heart and Generx Clinical Development
Date:11/15/2010

easing levels of cardiovascular disease in emerging market countries. Our Generx product candidate could potentially be developed as a front-line therapy for patients with coronary artery disease who often do not have access to costly advanced care procedures such as coronary angioplasty and stenting, or cardiac bypass surgery."  

About Generx The Generx™ (alferminogene tadenovec, Ad5FGF-4) product candidate represents a new class of cardiovascular biologics that is being developed to leverage the body's natural healing processes in response to repeated ischemic stress (insufficient blood flow and myocardial oxygen supply due to coronary heart disease).  The natural biologic response to repeated transient ischemia is angiogenesis, the growth of new collateral blood vessels, which is orchestrated by a complex and incompletely understood cascade involving many myocardial-derived growth factors.  These newly-formed vessels can effectively augment blood flow and oxygen delivery to parts of the patient's heart downstream from a blockage in a coronary artery.  In many patients however, including those with recurrent angina, coronary collateral vessel formation is insufficient to meet the heart's needs during stress.  Currently available anti-anginal drugs, which may provide symptomatic relief, are generally designed to alter the oxygen demand of the heart muscle or dilate vessels to temporarily relieve angina.  Generx is an angiogenic therapeutic product candidate that is designed to promote the heart's natural response of collateral growth and to increase blood flow in the microcirculation. In contrast to the transient symptomatic relief by marketed anti-anginal medicines, usually taken several times a day for years, a single administration of Generx aims at modifying the disease by permanent or long-lasting structural changes in the heart.

Researchers believe that central to the biological activity and potential thera
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology news :

1. Aware, Inc. Reports Third Quarter 2010 Financial Results
2. Smithsonian reports regional sea temperature rise and coral bleaching event in Western Caribbean
3. Novocure reports data showing TTF therapy in combination with chemotherapy has the potential to increase overall survival for patients with advanced non-small cell lung cancer
4. Terumo Medical Corp. reports first US implant in landmark study enrolling in US and Japan
5. GEN reports on the greening of the life sciences
6. Aware, Inc. Reports Second Quarter 2010 Financial Results
7. GEN reports on rediscovered technology to bolster proteomics research
8. BIO-key® Reports Strong 2010 Second Quarter and Six Month Financial Results
9. International Drug & Explosives Detection Company IDenta Corp Reports on BTK- Bullet Hole Testing Kit
10. Cell Transplantation reports consistent and successful islet isolations offer diabetes hope
11. New climate change reports underscore need for action
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2014)... of biology in the UTSA College of Sciences, ... selected to receive a two-year $300,00 National Science ... (EAGER). The funding supports President Obama,s BRAIN Initiative, ... new technology that will demystify complex brain processes. ... neuroscience are broken into the interactions of multiple ...
(Date:11/5/2014)... Brazil -Individuals show great diversity in their ability to ... females greatly differ in their perceptual evaluation of odors, ... tests. , Sex differences in olfactory detection ... may be connected to one,s perception of smell, which ... women,s olfactory superiority has been suggested to be cognitive ...
(Date:11/4/2014)... death at the right time might actually help boost ... could help in understanding animal populations, pest control and ... in the journal Trends in Ecology and Evolution ... that the kind of positive population effect an overall ... depends on the size and developmental stage of the ...
Breaking Biology News(10 mins):UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3The female nose always knows: Do women have more olfactory neurons? 2When less is more: Death in moderation boosts population density in nature 2
... July 11, 2012 Researchers at the Translational Genomics ... that could lead to a less costly, less invasive and ... CKD is a major complication of diabetes, high blood ... which is characterized by a progressive deterioration of the kidney,s ...
... scientists and research collaborators will present their work to ... of human animal interaction (HAI) at the ISAZ 2012 ... ISAZ 2012, a cross-disciplinary conference hosted by the International ... range of topics central to the field of human ...
... to impact the mating choices of fish, a new ... oestrogen-like properties, was found to alter an individual,s appearance ... in Evolutionary Applications , reveals the threat to ... The research, led by Dr Jessica Ward from ...
Cached Biology News:TGen method isolates biospecimens for treatment of kidney disease 2WALTHAM® demonstrates commitment to scientific dialogue and exchange at international human animal interaction conference 2Hormone-mimicking chemicals cause inter-species mating 2
(Date:11/24/2014)... November 24, 2014 2014 Deep ... Industry is a professional and in-depth research report ... Dihydrazide information, like its definition, classification, application, and ... This report covers the international market analysis, including ... as the US, Europe, Asia, China, Japan etc. ...
(Date:11/24/2014)... -- Senior Vice President, General Manager for ... business acumen Elsevier , a world-leading ... services, congratulates Diane Bartoli , Senior Vice President ... Clinical Solutions, for being recognized in the 13 th ... of Profiles in Diversity Journal ® . ...
(Date:11/22/2014)... 2014 During his lifetime Richard L. ... to surround himself with great people and take risks ... friends often marveled at his extraordinarily courageous attitude when ... and -- even with his death impending—that’s how he ... that would ultimately take his life. , Carrying on ...
(Date:11/22/2014)... Frederick, MD (PRWEB) November 21, 2014 ... sample management solutions provider, has released Limfinity® version ... more installation projects of Limfinity® than ever in ... majority configuration and minority framework enhancement. Limfinity® version ... goes far above and beyond bug fixes! , ...
Breaking Biology Technology:Adipic Dihydrazide Industry 2019 Research Forecasts on Worldwide, China Regions Now Available at ReportsnReports.com 2Adipic Dihydrazide Industry 2019 Research Forecasts on Worldwide, China Regions Now Available at ReportsnReports.com 3Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 3Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3RURO Announces Limfinity® version 5.1.4 2
... 1 Anesiva,Inc. (Nasdaq: ANSV ) will announce ... markets close on Thursday, May 8, 2008 and will ... Members of Anesiva,s,management team will discuss financial results from ... company,s product pipeline, recent events,and milestones., Interested parties ...
... -- Pharmaxis,(AXS: PSX; Nasdaq: PXSL) today announced that ... and Drug Administration (FDA) on the design of ... clearing agent, Bronchitol, in,patients with bronchiectasis., The ... daily in approximately 300 adults with bronchiectasis. Participants,will ...
... - Oncothyreon Inc. (Nasdaq:,ONTY) (TSX:ONY) today announced ... (IND) application with the U.S. Food and ... (PI-3-kinase),inhibitor for the treatment of advanced cancers. ... Phase 1 clinical trial of PX-866., ...
Cached Biology Technology:Anesiva Announces First Quarter 2008 Financial Results Conference Call and Webcast 2Regulatory Path for Bronchitol in Bronchiectasis 2Regulatory Path for Bronchitol in Bronchiectasis 3Oncothyreon files investigational new drug application for PX-866 oncology compound 2Oncothyreon files investigational new drug application for PX-866 oncology compound 3
... suitable for use in the Microsart e.motion are ... filter, in a specially designed individual package on ... the band of membrane filter units ensures that ... of the sealed band guarantees uniform dispensing of ...
...
... Variable Speed Rocker, with 12" x 14" table; ... x 14" table; 220V. The VSR-50 Variable ... for any lab. The VSR-50 provides a rhythmic ... a gentle to vigourous movement. This makes it ...
...
Biology Products: